The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Biologic Drugs Market Research Report 2024
Synopsis
The global Biologic Drugs market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Biologic Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Biologic Drugs.
Report Scope
The Biologic Drugs market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Biologic Drugs market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Biologic Drugs manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Roche
Abbott Laboratories
Johnson & Johnson
Merck & Co.
Pfizer
Amgen
Sanofi
Novartis
Eli Lilly
Amgen
Segment by Type
Humira
Remicade
Rituxan
Enbrel
Lantus
Avastin
Herceptin
Others
Segment by Application
Diabetes
Inflammation
Auto-Immune Diseases
Blood Diseases
Cardiovascular Diseases
Others
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Biologic Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Biologic Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
The global Biologic Drugs market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Biologic Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Biologic Drugs.
Report Scope
The Biologic Drugs market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Biologic Drugs market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Biologic Drugs manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Roche
Abbott Laboratories
Johnson & Johnson
Merck & Co.
Pfizer
Amgen
Sanofi
Novartis
Eli Lilly
Amgen
Segment by Type
Humira
Remicade
Rituxan
Enbrel
Lantus
Avastin
Herceptin
Others
Segment by Application
Diabetes
Inflammation
Auto-Immune Diseases
Blood Diseases
Cardiovascular Diseases
Others
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Biologic Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Biologic Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Index1 Biologic Drugs Market Overview
1.1 Product Overview and Scope of Biologic Drugs
1.2 Biologic Drugs Segment by Type
1.2.1 Global Biologic Drugs Market Value Comparison by Type (2024-2030)
1.2.2 Humira
1.2.3 Remicade
1.2.4 Rituxan
1.2.5 Enbrel
1.2.6 Lantus
1.2.7 Avastin
1.2.8 Herceptin
1.2.9 Others
1.3 Biologic Drugs Segment by Application
1.3.1 Global Biologic Drugs Market Value by Application: (2024-2030)
1.3.2 Diabetes
1.3.3 Inflammation
1.3.4 Auto-Immune Diseases
1.3.5 Blood Diseases
1.3.6 Cardiovascular Diseases
1.3.7 Others
1.4 Global Biologic Drugs Market Size Estimates and Forecasts
1.4.1 Global Biologic Drugs Revenue 2019-2030
1.4.2 Global Biologic Drugs Sales 2019-2030
1.4.3 Global Biologic Drugs Market Average Price (2019-2030)
1.5 Assumptions and Limitations
2 Biologic Drugs Market Competition by Manufacturers
2.1 Global Biologic Drugs Sales Market Share by Manufacturers (2019-2024)
2.2 Global Biologic Drugs Revenue Market Share by Manufacturers (2019-2024)
2.3 Global Biologic Drugs Average Price by Manufacturers (2019-2024)
2.4 Global Biologic Drugs Industry Ranking 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Biologic Drugs, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Biologic Drugs, Product Type & Application
2.7 Biologic Drugs Market Competitive Situation and Trends
2.7.1 Biologic Drugs Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Biologic Drugs Players Market Share by Revenue
2.7.3 Global Biologic Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Biologic Drugs Retrospective Market Scenario by Region
3.1 Global Biologic Drugs Market Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global Biologic Drugs Global Biologic Drugs Sales by Region: 2019-2030
3.2.1 Global Biologic Drugs Sales by Region: 2019-2024
3.2.2 Global Biologic Drugs Sales by Region: 2025-2030
3.3 Global Biologic Drugs Global Biologic Drugs Revenue by Region: 2019-2030
3.3.1 Global Biologic Drugs Revenue by Region: 2019-2024
3.3.2 Global Biologic Drugs Revenue by Region: 2025-2030
3.4 North America Biologic Drugs Market Facts & Figures by Country
3.4.1 North America Biologic Drugs Market Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America Biologic Drugs Sales by Country (2019-2030)
3.4.3 North America Biologic Drugs Revenue by Country (2019-2030)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe Biologic Drugs Market Facts & Figures by Country
3.5.1 Europe Biologic Drugs Market Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe Biologic Drugs Sales by Country (2019-2030)
3.5.3 Europe Biologic Drugs Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Biologic Drugs Market Facts & Figures by Country
3.6.1 Asia Pacific Biologic Drugs Market Size by Country: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific Biologic Drugs Sales by Country (2019-2030)
3.6.3 Asia Pacific Biologic Drugs Revenue by Country (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.7 Latin America Biologic Drugs Market Facts & Figures by Country
3.7.1 Latin America Biologic Drugs Market Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America Biologic Drugs Sales by Country (2019-2030)
3.7.3 Latin America Biologic Drugs Revenue by Country (2019-2030)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Biologic Drugs Market Facts & Figures by Country
3.8.1 Middle East and Africa Biologic Drugs Market Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa Biologic Drugs Sales by Country (2019-2030)
3.8.3 Middle East and Africa Biologic Drugs Revenue by Country (2019-2030)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Biologic Drugs Sales by Type (2019-2030)
4.1.1 Global Biologic Drugs Sales by Type (2019-2024)
4.1.2 Global Biologic Drugs Sales by Type (2025-2030)
4.1.3 Global Biologic Drugs Sales Market Share by Type (2019-2030)
4.2 Global Biologic Drugs Revenue by Type (2019-2030)
4.2.1 Global Biologic Drugs Revenue by Type (2019-2024)
4.2.2 Global Biologic Drugs Revenue by Type (2025-2030)
4.2.3 Global Biologic Drugs Revenue Market Share by Type (2019-2030)
4.3 Global Biologic Drugs Price by Type (2019-2030)
5 Segment by Application
5.1 Global Biologic Drugs Sales by Application (2019-2030)
5.1.1 Global Biologic Drugs Sales by Application (2019-2024)
5.1.2 Global Biologic Drugs Sales by Application (2025-2030)
5.1.3 Global Biologic Drugs Sales Market Share by Application (2019-2030)
5.2 Global Biologic Drugs Revenue by Application (2019-2030)
5.2.1 Global Biologic Drugs Revenue by Application (2019-2024)
5.2.2 Global Biologic Drugs Revenue by Application (2025-2030)
5.2.3 Global Biologic Drugs Revenue Market Share by Application (2019-2030)
5.3 Global Biologic Drugs Price by Application (2019-2030)
6 Key Companies Profiled
6.1 Roche
6.1.1 Roche Corporation Information
6.1.2 Roche Description and Business Overview
6.1.3 Roche Biologic Drugs Sales, Revenue and Gross Margin (2019-2024)
6.1.4 Roche Biologic Drugs Product Portfolio
6.1.5 Roche Recent Developments/Updates
6.2 Abbott Laboratories
6.2.1 Abbott Laboratories Corporation Information
6.2.2 Abbott Laboratories Description and Business Overview
6.2.3 Abbott Laboratories Biologic Drugs Sales, Revenue and Gross Margin (2019-2024)
6.2.4 Abbott Laboratories Biologic Drugs Product Portfolio
6.2.5 Abbott Laboratories Recent Developments/Updates
6.3 Johnson & Johnson
6.3.1 Johnson & Johnson Corporation Information
6.3.2 Johnson & Johnson Description and Business Overview
6.3.3 Johnson & Johnson Biologic Drugs Sales, Revenue and Gross Margin (2019-2024)
6.3.4 Johnson & Johnson Biologic Drugs Product Portfolio
6.3.5 Johnson & Johnson Recent Developments/Updates
6.4 Merck & Co.
6.4.1 Merck & Co. Corporation Information
6.4.2 Merck & Co. Description and Business Overview
6.4.3 Merck & Co. Biologic Drugs Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Merck & Co. Biologic Drugs Product Portfolio
6.4.5 Merck & Co. Recent Developments/Updates
6.5 Pfizer
6.5.1 Pfizer Corporation Information
6.5.2 Pfizer Description and Business Overview
6.5.3 Pfizer Biologic Drugs Sales, Revenue and Gross Margin (2019-2024)
6.5.4 Pfizer Biologic Drugs Product Portfolio
6.5.5 Pfizer Recent Developments/Updates
6.6 Amgen
6.6.1 Amgen Corporation Information
6.6.2 Amgen Description and Business Overview
6.6.3 Amgen Biologic Drugs Sales, Revenue and Gross Margin (2019-2024)
6.6.4 Amgen Biologic Drugs Product Portfolio
6.6.5 Amgen Recent Developments/Updates
6.7 Sanofi
6.6.1 Sanofi Corporation Information
6.6.2 Sanofi Description and Business Overview
6.6.3 Sanofi Biologic Drugs Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Sanofi Biologic Drugs Product Portfolio
6.7.5 Sanofi Recent Developments/Updates
6.8 Novartis
6.8.1 Novartis Corporation Information
6.8.2 Novartis Description and Business Overview
6.8.3 Novartis Biologic Drugs Sales, Revenue and Gross Margin (2019-2024)
6.8.4 Novartis Biologic Drugs Product Portfolio
6.8.5 Novartis Recent Developments/Updates
6.9 Eli Lilly
6.9.1 Eli Lilly Corporation Information
6.9.2 Eli Lilly Description and Business Overview
6.9.3 Eli Lilly Biologic Drugs Sales, Revenue and Gross Margin (2019-2024)
6.9.4 Eli Lilly Biologic Drugs Product Portfolio
6.9.5 Eli Lilly Recent Developments/Updates
6.10 Amgen
6.10.1 Amgen Corporation Information
6.10.2 Amgen Description and Business Overview
6.10.3 Amgen Biologic Drugs Sales, Revenue and Gross Margin (2019-2024)
6.10.4 Amgen Biologic Drugs Product Portfolio
6.10.5 Amgen Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Biologic Drugs Industry Chain Analysis
7.2 Biologic Drugs Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Biologic Drugs Production Mode & Process
7.4 Biologic Drugs Sales and Marketing
7.4.1 Biologic Drugs Sales Channels
7.4.2 Biologic Drugs Distributors
7.5 Biologic Drugs Customers
8 Biologic Drugs Market Dynamics
8.1 Biologic Drugs Industry Trends
8.2 Biologic Drugs Market Drivers
8.3 Biologic Drugs Market Challenges
8.4 Biologic Drugs Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
